Our promise to patients: You come first
We are here so that you don’t have to suffer in silence
At CSL Behring, patients always come first. We understand serious and rare diseases because we've specialized in them for decades. By working closely with patients and their, we're able to identify and pursue new innovations that address unmet medical needs. Meanwhile, we continue to enhance our current treatments for rare diseases, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, and hereditary angioedema.
We are driven by our promise to save lives and improve the quality of life for our patients and their families, because living with a rare disease impacts more than just one person. Through our local partners, we collaborate with patient advocacy organizations to improve and expand educational and outreach efforts. We also work with government authorities to ensure patients have access to the medicines they need to live life to the fullest.
Suffer in Silence: White Paper on Rare Disease Awareness
To truly understand the realities facing patients living with rare diseases in Asia, CSL Behring commissioned The Economist Intelligence Unit (EIU) to explore the state of rare-disease understanding and management throughout the Asia-Pacific region
CSL CEO Paul Perreault on Rare Disease Day
At CSL, people work for patients and public health 365 days a year, but Rare Disease Day is an especially good time to remember why this work matters. See the video Perreault shared with employees on Rare Disease Day: “Reflect on the many contributions each of us make to help deliver on our promise to patients with rare and serious diseases around the world.”Watch the full video on CSLBehring.com